Cameron Mattingly
Overview
Explore the profile of Cameron Mattingly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uddback I, Michalets S, Saha A, Mattingly C, Kost K, Williams M, et al.
Nature
. 2023 Dec;
626(7998):392-400.
PMID: 38086420
An ideal vaccine both attenuates virus growth and disease in infected individuals and reduces the spread of infections in the population, thereby generating herd immunity. Although this strategy has proved...
2.
Mavigner M, Liao L, Brooks A, Ke R, Mattingly C, Schoof N, et al.
J Virol
. 2021 Feb;
95(8).
PMID: 33568515
Inducing latency reversal to reveal infected cells to the host immune system represents a potential strategy to cure HIV infection. In separate studies, we have previously shown that CD8 T...
3.
Raper J, Kovacs-Balint Z, Mavigner M, Gumber S, Burke M, Habib J, et al.
Nat Commun
. 2020 May;
11(1):2534.
PMID: 32439858
Zika virus (ZIKV) infection has a profound impact on the fetal nervous system. The postnatal period is also a time of rapid brain growth, and it is important to understand...
4.
Mavigner M, Habib J, Deleage C, Rosen E, Mattingly C, Bricker K, et al.
J Virol
. 2020 Apr;
94(8).
PMID: 32234801
No abstract available.
5.
Nixon C, Mavigner M, Sampey G, Brooks A, Spagnuolo R, Irlbeck D, et al.
Nature
. 2020 Jan;
578(7793):160-165.
PMID: 31969707
Long-lasting, latently infected resting CD4 T cells are the greatest obstacle to obtaining a cure for HIV infection, as these cells can persist despite decades of treatment with antiretroviral therapy...
6.
Goswami R, Nelson A, Tu J, Dennis M, Feng L, Kumar A, et al.
mBio
. 2019 Sep;
10(5).
PMID: 31488511
To achieve long-term viral remission in human immunodeficiency virus (HIV)-infected children, novel strategies beyond early antiretroviral therapy (ART) will be necessary. Identifying clinical predictors of the time to viral rebound...
7.
Mavigner M, Habib J, Deleage C, Rosen E, Mattingly C, Bricker K, et al.
J Virol
. 2019 Jan;
93(3).
PMID: 30655382
No abstract available.
8.
Kumar N, McBrien J, Carnathan D, Mavigner M, Mattingly C, White E, et al.
J Virol
. 2018 Sep;
92(22).
PMID: 30185596
A major barrier to human immunodeficiency virus (HIV) eradication is the long-term persistence of latently infected CD4 T cells harboring integrated replication-competent virus. It has been proposed that the homeostatic...
9.
Mavigner M, Habib J, Deleage C, Rosen E, Mattingly C, Bricker K, et al.
J Virol
. 2018 Jul;
92(18).
PMID: 29997216
Worldwide, nearly two million children are infected with human immunodeficiency virus (HIV), with breastfeeding accounting for the majority of contemporary HIV transmissions. Antiretroviral therapy (ART) has reduced HIV-related morbidity and...
10.
Palesch D, Bosinger S, Mavigner M, Billingsley J, Mattingly C, Carnathan D, et al.
J Virol
. 2018 May;
92(14).
PMID: 29720521
The major obstacle to human immunodeficiency type 1 (HIV-1) eradication is a reservoir of latently infected cells that persists despite long-term antiretroviral therapy (ART) and causes rapid viral rebound if...